Incyte

Incyte Corporation is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel medicines. Its core mission is to address serious unmet medical needs and improve the lives of patients worldwide through proprietary therapeutics. The company's global headquarters are located in Wilmington, Delaware, United States, with plans to consolidate its corporate headquarters in downtown Wilmington by 2026.

Incyte focuses its research and development efforts across three primary therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity, which includes dermatology. Key marketed products include Jakafi (ruxolitinib), a leading treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD), and Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo. The company's portfolio also features other oncology drugs such as Pemazyre (pemigatinib) and Monjuvi (tafasitamab-cxix), and it has licensed products like Olumiant (baricitinib) to Eli Lilly and Tabrecta (capmatinib) to Novartis. Incyte primarily serves specialized healthcare providers, including hematologists, oncologists, dermatologists, and rheumatologists, with significant market presence in North America, Europe, and Asia.

Under the leadership of CEO and President Bill Meury, who joined in 2025, Incyte has demonstrated strong financial performance, reporting robust Q1 2026 results with a 20% year-over-year net sales growth. While Jakafi remains a significant revenue driver, Incyte is actively diversifying its product offerings with the successful launch of Opzelura and new products like Niktimvo. The company is strategically expanding its pipeline, with multiple new product launches and pivotal trial readouts anticipated in 2025 and 2026, and aims for over 10 impactful product launches by 2030. In May 2024, Incyte further strengthened its portfolio through the acquisition of Escient Pharmaceuticals, adding new oral drug candidates for inflammatory diseases.